Kevin B Kim, M.D.
Investigator
Dr. Kim is a recognized expert in the field of melanoma, and his research has focused on targeted therapy and immunotherapy. His research has helped early clinical development of BRAF inhibitors, such as vemurafenib, dabrafenib, MEK inhibitors, and trametinib, which are now standard of care for patients with BRAF mutated melanoma. His research has also included the clinical investigation of therapy for other mutations, including cKIT and NRAS and also antiangiogenic drugs as well as novel immunotherapy, such as ipilimumab, anti-PD1 antibodies and cancer vaccines. He is also a senior editor for the journal Melanoma Management.
Research studies
- Research study
Melanoma Follow Up R3767-ONC-2466
Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613
Clinical trials
- Clinical trial
Adjuvant Non Small Lung Cancer TroFuse-019
A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery (MK-2870-019) (TroFuse-019)
Status: Open to Enrollment
- Clinical trial
Advanced Melanoma Ignyte-3
Randomized, Ph3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination With Nivolumab Vs Treatment of Physician's Choice in Patients With Advanced Melanoma That Progressed on Anti-PD-1 and Anti-CTLA-4 Containing Treatment
Status: Open to Enrollment
- Clinical trial
Advanced Melanoma Mirdametinib CPMC24-MEL01
A Pilot Study of Mirdametinib in Patients With Advanced Melanoma With an NF1 Mutation (CPMC24-MEL01)
Status: Open to Enrollment
A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Status: Open to Enrollment
- Clinical trial
Metastatic Non-small Cell Lung Cancer RELATIVITY1093
A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%
Status: Open to Enrollment